Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed/refractory multiple myeloma bearing the translocation t(11;14)

Trial Details

NCT ID
NCT05853965
Phase
PHASE1 / PHASE2
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Belantamab mafodotin, Venetoclax
Locations (sample)
  • Hamburg, Ham, Germany|53.55073,9.99302
  • Chemnitz, Germany|50.8357,12.92922
  • Heidelberg, Germany|49.40768,8.69079
  • Lübeck, Germany|53.86893,10.68729
  • Ulm, Germany|48.39841,9.99155

Key Eligibility Criteria

  • Subjects must be ≥ 18 years of age.
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Subjects must voluntarily sign and date an in-formed consent form
  • Subjects must have had documented multiple myeloma requiring treatment as defined by the criteria below:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →